University of Utah: Thrombosis trials

The registry lists 14 Thrombosis studies with University of Utah as lead sponsor. 0 are open to participants now and 7 have results posted.

Early Phase 1 3Phase 1 1Phase 2 4Phase 4 3No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Weight-Based Enoxaparin Dosing and Real-Time Dose Adjustment in Orthopaedic TraumaCompletedNCT03339349Phase 2Results posted
• Fixed Versus Weight-Based Enoxaparin Dosing in Thoracic Surgery PatientsCompletedNCT03251963Phase 2Results posted
• Minimization of Bleeding Related Adverse Drug Events in Plastic & Reconstructive SurgeryCompletedNCT03212365Phase 2Results posted
• Evaluation of Anti-Xa Levels in Surgery Patients Receiving Fixed Dose HeparinCompletedNCT02970032Early Phase 1Results posted
• Enoxaparin Metabolism in Reconstructive Surgery PatientsCompletedNCT02411292Phase 2Results posted
• Efficacy of Optison Echo Contrast to Detect Thrombus in Left Atrial AppendageCompletedNCT01721447Phase 4Results posted
• Study to Evaluate Weight-based Enoxaparin Dosing in Obese Medical Patients at Risk for DVTCompletedNCT00585182Phase 4Results posted
• Non-Interruptive Alerts for Improving Use of Clinical Decision RulesCompletedNCT04702308Not applicable
• Impact of Prophylactic Low-molecular Weight Heparin Dosing on Clotting Parameters Following Cesarean DeliveryCompletedNCT04305756Not applicable
• Enoxaparin Versus Placebo for Venous Thromboembolism Prevention in Low Risk Cancer Patients After Surgical Procedures: a Randomized, Double Blind, Placebo Controlled Clinical Trial Pilot StudyWithdrawnNCT03988231Phase 4
• Fearon Algorithm in Warfarin Patient Self-ManagementCompletedNCT03911661Not applicable
• Evaluation of Anti-Xa Levels in Surgery Patients Receiving Weight-based HeparinCompletedNCT03516656Early Phase 1
• Real-time Anti-Factor Xa Measurements in Surgical Patients to Examine Enoxaparin Metabolism and Optimize Enoxaparin DoseCompletedNCT02704052Early Phase 1
• Twice Daily Enoxaparin Prophylaxis in Reconstructive Surgery PatientsCompletedNCT02687204Phase 1